BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Halyabar O, Mehta J, Ringold S, Rumsey DG, Horton DB. Treatment Withdrawal Following Remission in Juvenile Idiopathic Arthritis: A Systematic Review of the Literature. Paediatr Drugs 2019;21:469-92. [PMID: 31673960 DOI: 10.1007/s40272-019-00362-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Choida V, Hall-Craggs M, Jebson BR, Fisher C, Leandro M, Wedderburn LR, Ciurtin C. Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis. Front Pharmacol 2020;11:635823. [PMID: 33603671 DOI: 10.3389/fphar.2020.635823] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol 2021;73:e46-59. [PMID: 34114365 DOI: 10.1002/art.41772] [Reference Citation Analysis]
3 Liao CH, Chiang BL, Yang YH. Tapering of Biological Agents in Juvenile ERA Patients in Daily Clinical Practice. Front Med (Lausanne) 2021;8:665170. [PMID: 34026793 DOI: 10.3389/fmed.2021.665170] [Reference Citation Analysis]
4 Chang MH, Shantha JG, Fondriest JJ, Lo MS, Angeles-Han ST. Uveitis in Children and Adolescents. Rheum Dis Clin North Am 2021;47:619-41. [PMID: 34635295 DOI: 10.1016/j.rdc.2021.07.005] [Reference Citation Analysis]
5 Castillo-Vilella M, Giménez N, Tandaipan JL, Quintana S, Modesto C. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach. Pediatr Rheumatol Online J 2021;19:130. [PMID: 34419078 DOI: 10.1186/s12969-021-00607-0] [Reference Citation Analysis]
6 Klein-Wieringa IR, Brinkman DMC, Ten Cate R, Hissink Muller PCE. Update on the treatment of nonsystemic juvenile idiopathic arthritis including treatment-to-target: is (drug-free) inactive disease already possible? Curr Opin Rheumatol 2020;32:403-13. [PMID: 32657803 DOI: 10.1097/BOR.0000000000000727] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Teh KL, Das L, Book YX, Hoh SF, Gao X, Arkachaisri T. Sacroiliitis at diagnosis as a protective predictor against disease flare after stopping medication: outcomes of a Southeast Asian enthesitis-related arthritis (ERA) longitudinal cohort. Clin Rheumatol 2022. [PMID: 35794290 DOI: 10.1007/s10067-022-06275-z] [Reference Citation Analysis]
8 Renton WD, Tiller G, Munro J, Tan J, Johnston RV, Avery JC, Whittle SL, Arno A, Buchbinder R; Cochrane Musculoskeletal Group. Dose reduction and discontinuation of disease-modifying anti-rheumatic drugs (DMARDs) for juvenile idiopathic arthritis. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014961] [Reference Citation Analysis]
9 Horton DB, Salas J, Wec A, Kohlheim M, Kapadia P, Beukelman T, Boneparth A, Haverkamp K, Mannion ML, Moorthy LN, Ringold S, Rosenthal M. Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers. Arthritis Care Res (Hoboken) 2021;73:374-85. [PMID: 31880862 DOI: 10.1002/acr.24129] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Gerss J, Tedy M, Klein A, Horneff G, Miranda-Garcia M, Kessel C, Holzinger D, Stanevica V, Swart JF, Cabral DA, Brunner HI, Foell D. Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial. Ann Rheum Dis 2022:annrheumdis-2021-222029. [PMID: 35260388 DOI: 10.1136/annrheumdis-2021-222029] [Reference Citation Analysis]
11 Maccora I, Sen ES, Ramanan AV. Update on noninfectious uveitis in children and its treatment. Curr Opin Rheumatol 2020;32:395-402. [PMID: 32675714 DOI: 10.1097/BOR.0000000000000723] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
12 Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 1. Arthritis Rheumatol 2020;72:1809-19. [PMID: 32705780 DOI: 10.1002/art.41455] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
13 Bridges JM, Mellins ED, Cron RQ. Recent progress in the treatment of non-systemic juvenile idiopathic arthritis. Fac Rev 2021;10:23. [PMID: 33718940 DOI: 10.12703/r/10-23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]